NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Cigna for its Veristrat test for guiding therapy in patients with non-small cell lung cancer.

The decision gives Biodesix more than 115 million covered lives for the test, which uses MALDI mass spec-based proteomic signatures to identify patients likely to respond to treatment with EGFR inhibitors. Cigna has 13.3 million US members.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.